What they say:
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature, by Prof Dimmler (Director, Center for Molecular Medicine), Boon, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular mechanistic insight into how Dapagliflozin (DAPA) protects against and promotes functional recovery after Myocardial Infarction: Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm
From Significance of the study to Public Health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From Research Findings to Therapeutic Opportunity:
A study from the BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; the Cardiovascular Division and the TIMI Study Group, Brigham and Women’s Hospital and Harvard Medical School and others shows that “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” This study was published, in the 19 September 2019 issue of of the prestigious journal N Engl J Med. (Impact factor: 7o +), by Prof. Langkilde AM., MD., PhD., McMurray JJV, M.D., and others. This study suggests that those patients who consumed Dapagliflozin (DAPA) are at reduced risk of major cardiovascular events. However, the precise mechanism of action of Dapagliflozin (DAPA) remains unclear.
The study presented here substantiates and supports the aforementioned study’s’ claim, and of others, by providing detailed mechanistic insights into how Dapagliflozin (DAPA) attenuates and thereby protects against myocardial dysfunction, including cardiac hypertrophy, fibrosis of the myocardium, cardiac ageing and myocardial infarction.
This study provides, for the first time, mechanistic insights into how Dapagliflozin (DAPA) may protect against myocardial dysfunction.
Dapagliflozin (DAPA), by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1). Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate aging; and (6) extend lifespan (fig 1).
Thus, by recommending aged cardiac patients to take Dapagliflozin (DAPA), one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests, for the first time, that pharmacological formulations encompassing “Dapagliflozin (DAPA) or its analogs or its functional or mechanistic equivalents, either alone or in combination with other drugs, may be used to protect against myocardial infarction or improve cardiac function after myocardial infarction (fig. 2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Dapagliflozin (DAPA) increase the expression of PNUTS/Telomerase?
Amount: $ 1, 500 #
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
Citation: Boominathan, L., Molecular mechanistic insight into how Dapagliflozin (DAPA) protects against and promotes functional recovery after Myocardial Infarction: Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org